Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Better Coronavirus Stock: Pfizer vs. BioNTech

By Jason Hawthorne - Dec 19, 2020 at 7:45AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One healthcare company is confident about its future while the other tries to recapture its former glory.

Mercedes or Porsche? Steak or sushi? Two things can both be good but very different. For investors, the best coronavirus stock may depend on who's choosing. Breaking down the pros and cons of Pfizer ( PFE 1.77% ) and BioNTech ( BNTX -4.91% ) reveals two very different companies linked by more than their partnership on a COVID-19 vaccine. So how do you choose between buying these two stocks, or do you really have to?

A nurse wearing a mask and a glove holds up a vial of Covid-19 vaccine.

Image source: Getty Images.

What the future holds

Pfizer and BioNTech are at opposite ends of the spectrum in terms of corporate lifespans. As a $218 billion company founded 170 years ago, Pfizer is about as old as companies get. With 92 treatments in various stages of clinical trials and 49 individual drugs generating $52 billion in revenue, Pfizer is the definition of a blue-chip stock. Perhaps because those sales sit exactly where they were in 2013, the company has been transforming itself. The moves include merging Upjohn, its off-patent drugs division, with Mylan to form a new entity named Viatris ( VTRS -1.79% ). With a renewed focus on more profitable oncology drugs and vaccines, Pfizer's management is betting that growth will return.

Unlike Pfizer, BioNTech was founded in 2008, and its paltry sales are associated with collaboration agreements, not commercialized drugs. Despite the lack of sales, the company sports a $26 billion market cap as investors anticipate the company's pending share of profits from the COVID-19 vaccine. There is more than the vaccine to generate excitement. In a 2017 study, the company's gene-based approach created increased immunity in skin cancer patients, preventing new lesions from forming. This result has encouraged its pursuit of treatments for cancer of the lungs, ovaries, breasts, prostate, head and neck, and solid tumors. The pipeline also contains an early-stage flu vaccine being developed with Pfizer.

The intangibles

There are other factors to consider beyond a drug pipeline and product sales when deciding between companies. Intangibles, such as leadership and the company's purpose may also help predict how the company will fare over the long term.

Pfizer CEO Albert Bourla has worked at the company for 25 years but only took the helm in 2019. A few of his decisions indicates an attempt to reshape the company from a stodgy old pharmaceutical company into an innovator as in its glory days as the world's largest pharmaceutical company. Announcing the Upjohn spinoff in 2019 sent a clear signal that the company wanted to streamline around faster-growing, more profitable medicines. Only a month earlier, the company had agreed to buy cancer drugmaker Array Pharmaceuticals for $11.4 billion.

Capital allocation isn't something BioNTech shareholders have to think much about as the company has yet to generate operating cash flow. The founders -- Dr. Ugur Sahin and Dr. Ozlem Tureci -- have a vision to individualize cancer medicine. This isn't their first company or the first time they've been at the cutting edge of medicine. In 2001, the married pair started a firm that developed monoclonal antibodies to treat cancer, selling it in 2016 for $1.4 billion. Although the couple has said they want to build a large pharmaceutical company, don't let those lofty aspirations make you think they are not interested in anything but science. The couple lives with their teenage daughter in a small apartment near the office and ride bicycles to work, according to a New York Times profile.

Which stock to buy?

One way to choose between two companies is to look at who else has chosen them as a partner. Since Pfizer is a large pharma company, it's no surprise they have a lot of relationships. What is surprising is how many organizations have chosen to partner with BioNTech. The list includes the Bill & Melinda Gates Foundation and large pharma companies such as Roche, Bayer, Eli Lilly, Sanofi, Genmab, and Regeneron. Pfizer was also a partner a few years before they teamed up on a COVID-19 vaccine.

With BioNTech, you get a company with focused leaders and a clear purpose at the cutting edge of medical research. Pfizer is doing its best to return to a time when it fit that description. The two companies will split the windfall associated with the COVID-19 vaccine but spend it in very different ways. For Pfizer, the success will fill the coffers leading to perhaps more acquisitions, dividends, or stock buybacks. The company already has more than $10 billion on the balance sheet. For BioNTech, the success represents fuel for the company's other development programs as it applies its now validated gene-based approach to other diseases. Both stocks may represent good investments, but the better coronavirus stock for me is BioNTech -- the company that knows what it is, not the one trying to get back to what it once was.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$54.68 (1.77%) $0.95
Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$249.13 (0.44%) $1.09
Sanofi Stock Quote
Sanofi
SNY
$48.06 (1.03%) $0.49
Regeneron Pharmaceuticals, Inc. Stock Quote
Regeneron Pharmaceuticals, Inc.
REGN
$630.59 (-0.93%) $-5.94
Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$49.14 (0.74%) $0.36
Bayer Stock Quote
Bayer
BAYR.Y
$12.79 (1.35%) $0.17
BioNTech SE Stock Quote
BioNTech SE
BNTX
$334.48 (-4.91%) $-17.26
Genmab A/S Stock Quote
Genmab A/S
GMAB
$38.00 (-1.35%) $0.52
Viatris Inc. Stock Quote
Viatris Inc.
VTRS
$12.09 (-1.79%) $0.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
656%
 
S&P 500 Returns
144%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/01/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.